CMS treats biosimilars as generics for the purposes of the part D coverage gap. It now wants to ensure that biosimilars are treated as generics in terms of the coverage gap for only those receiving low-income subsidies.
Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy